Shares of Endologix, Inc. (NASDAQ:ELGX) have been assigned an average rating of “Hold” from the thirteen brokerages that are presently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation and eleven have issued a hold recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $6.33.

Several analysts have commented on ELGX shares. Canaccord Genuity restated a “hold” rating on shares of Endologix in a research note on Friday, August 4th. BidaskClub cut shares of Endologix from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Oppenheimer Holdings, Inc. set a $5.00 price objective on shares of Endologix and gave the company a “hold” rating in a research note on Thursday, August 3rd. Stifel Nicolaus set a $6.00 price objective on shares of Endologix and gave the company a “hold” rating in a research note on Wednesday, August 2nd. Finally, Royal Bank Of Canada restated a “hold” rating and set a $5.00 price objective on shares of Endologix in a research note on Tuesday, October 3rd.

Large investors have recently bought and sold shares of the company. Swiss National Bank increased its holdings in shares of Endologix by 14.3% during the 2nd quarter. Swiss National Bank now owns 137,900 shares of the medical instruments supplier’s stock valued at $670,000 after purchasing an additional 17,300 shares in the last quarter. American International Group Inc. increased its holdings in shares of Endologix by 7.1% during the 1st quarter. American International Group Inc. now owns 49,906 shares of the medical instruments supplier’s stock valued at $361,000 after purchasing an additional 3,290 shares in the last quarter. Stephens Inc. AR increased its holdings in shares of Endologix by 10.5% during the 2nd quarter. Stephens Inc. AR now owns 845,016 shares of the medical instruments supplier’s stock valued at $4,107,000 after purchasing an additional 80,328 shares in the last quarter. Schwab Charles Investment Management Inc. increased its holdings in shares of Endologix by 10.5% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 321,309 shares of the medical instruments supplier’s stock valued at $1,562,000 after purchasing an additional 30,429 shares in the last quarter. Finally, Teachers Advisors LLC increased its holdings in shares of Endologix by 40.8% during the 2nd quarter. Teachers Advisors LLC now owns 198,912 shares of the medical instruments supplier’s stock valued at $967,000 after purchasing an additional 57,675 shares in the last quarter.

TRADEMARK VIOLATION WARNING: “Endologix, Inc. (ELGX) Receives Consensus Rating of “Hold” from Brokerages” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/11/05/endologix-inc-elgx-receives-consensus-rating-of-hold-from-brokerages-2.html.

Shares of Endologix (ELGX) opened at $5.92 on Friday. The company has a quick ratio of 2.12, a current ratio of 2.82 and a debt-to-equity ratio of 2.28. Endologix has a 12 month low of $4.08 and a 12 month high of $10.36.

Endologix (NASDAQ:ELGX) last released its earnings results on Wednesday, August 2nd. The medical instruments supplier reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.08. The company had revenue of $48.60 million during the quarter, compared to analysts’ expectations of $47.58 million. Endologix had a negative net margin of 40.77% and a negative return on equity of 46.32%. Endologix’s revenue for the quarter was down 4.6% on a year-over-year basis. During the same period last year, the business earned ($0.20) EPS. research analysts forecast that Endologix will post -0.71 EPS for the current fiscal year.

About Endologix

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

Analyst Recommendations for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.